Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.51 |
| ▸ | PPARA | Q07869 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338001 | 1.00 | PPARG (0.51) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL1714102 | 1.00 | PPARG (0.51) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL541965 | 1.00 | PPARG (0.51) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL1714197 | 1.00 | PPARG (0.51) | PPARGPPARALMNAL3MBTL1KMT2A | |
| Water SCHEMBL3347709 | 0.98 | PPARG (0.50) | PPARGPPARALMNAL3MBTL1KMT2A | |
| Water SCHEMBL2789432 | 0.98 | PPARG (0.50) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL27510640 | 0.90 | PPARG (0.45) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL11708010 | 0.90 | PPARG (0.53) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL1974348 | 0.88 | PPARG (0.54) | PPARGPPARALMNAL3MBTL1KMT2A | |
| SCHEMBL2952466 | 0.88 | PPARG (0.54) | PPARGPPARALMNAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024110862-A9 | PROCESS FOR PREPARING ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-11-28 | — | — | WO | claimed |
| WO-2024110862-A1 | PROCESS FOR PREPARING ZANUBRUTINIB | OLON S.P.A. (IT) | 2024-05-30 | — | — | WO | claimed |
| EP-3336079-A1 | (-)-(2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YL-PROPAN-1-ONE (L)-(+) TARTRATE SALT, ITS METHOD OF PRODUCTION AND USE | ALLERGAN, INC. (US) | 2018-06-20 | — | — | EP | claimed |
| EP-3033327-B1 | (-)-(2R,3S)-2-AMINO-3-HYDROXY-3-PYRIDIN-4-YL-1-PYRROLIDIN-1-YL-PROPAN-1-ONE (L)-(+) TARTRATE SALT, ITS METHOD OF PRODUCTION AND USE | ALLERGAN INC (US) | 2018-01-03 | — | — | EP | claimed |
| EP-1884514-B1 | METHOD FOR THE RESOLUTION OF 2-AMINO-6-PROPYLAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOL AND INTERMEDIATE COMPOUNDS | CRYSTAL PHARMA SAU (ES) | 2017-04-12 | — | — | EP | claimed |
| US-9242935-B2 | (-)-(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-yl-propan-1-one (L)-(+) tartrate salt, its method of production and use | ALLERGAN, INC. (US) | 2016-01-26 | — | — | US | claimed |
| EP-2155756-B1 | PROCESSES FOR THE PREPARATION OF CLOPIDOGREL | WOCKHARDT LTD (IN) | 2015-08-05 | — | — | EP | claimed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | claimed |
| EP-2686288-B1 | A PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2015-03-25 | — | — | EP | claimed |
| US-8952173-B2 | Method for the resolution of 2-amino-6-propylamino-4,5,6,7-tetrahydrobenzothiazol and intermediate compounds | CRYSTAL PHARMA, S.A.U. (ES) | 2015-02-10 | — | — | US | claimed |
| US-6855820-B2 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-15 | — | — | US | claimed |
| CN-1575282-A | Lactam compound | LILLY CO ELI (US) | 2005-02-02 | — | — | CN | claimed |
| US-20040248878-A1 | Lactam compound | KOENIG THOMAS MITCHELL (US) | 2004-12-09 | — | — | US | claimed |
| EP-1353910-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2003-10-22 | — | — | EP | claimed |
| EP-1024137-B1 | RESOLUTION OF AMINES | ESTEVE LABOR DR (ES) | 2003-09-24 | — | — | EP | claimed |
| US-20030027827-A1 | Pharmaceutically active morpholinol | SMITHKLINE BEECHAM CORPORATION | 2003-02-06 | — | — | US | claimed |
| WO-2002040451-A2 | LACTAM COMPOUND | ELI LILLY AND COMPANY (US) | 2002-05-23 | — | — | WO | claimed |
| US-6187930-B1 | REACTING SELECTED AMINE WITH OPTICALLY ACTIVE ACID SELECTED FROM (+)-DITOLUYL-L-TARTARIC ACID AND/OR (-)-DITOLUYL-L-TARTARIC ACID IN SOLVENT TO FORM DIASTEROISOMERIC SALT, SEPARATING, ISOLATING ENANTIOMER | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-02-13 | — | — | US | claimed |
| EP-1024137-A1 | RESOLUTION OF AMINES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2000-08-02 | — | — | EP | claimed |
| US-4458084-A | Cyclopentene derivatives | THE UPJOHN COMPANY (US) | 1984-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248878-A1 | Lactam compound | AAAS, CHLSN, APH1B | PPARG 3679/4885PPARA 3343/4885LMNA 919/4885 |
| US-20030027827-A1 | Pharmaceutically active morpholinol | ACHE, COMT, MGLL | PPARG 2515/4885PPARA 2398/4885LMNA 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.